SUMMARY, EXPLANATION AND LIMITATIONS:
Beta-catenin is involved in cell adhesion through catenin-cadherin complexes and as a transcriptional regulator in the Wnt signaling pathway. Its deregulation is important in the genesis of a number of human malignancies, particularly colorectal cancer. The β- Catenin adhesion complex is crucial for intercellular adhesiveness and maintenance of tissue architecture. Its impairment is associated with poorly differentiated phenotype and increased invasiveness of carcinomas. Dysregulation of these pathways allow Beta-catenin to accumulate and translocate to the nucleus, where it may activate oncogenes. Such nuclear accumulation can be detected by immunohistochemistry, which may be useful in diagnosis. Catenins link E-cadherin to other integral membrane or cytoplasmic proteins and are modulated by Wnt1 proto-oncogene. The central core region of β-Catenin is involved in mediation of cadherin complex interaction with EGFR. β- Catenin signaling has been shown to have a role in the regulation of angiogenesis and cytoplasmic localization of β-Catenin has been demonstrated as a marker of poor outcome in breast cancer patients.
Immunogen: Beta-catenin aa 571-781.
Staining pattern: Cytoplasm, cell membrane and nucleus.
Positive control: Tissue sample from colon or breast carcinoma.
This antibody is designed for the specific localization of human b-catenin using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
This antibody has been described as a useful marker for the discrimination of lobular and ductal lesions of the breast.